KIDS logo

OrthoPediatrics Corp. Stock Price

NasdaqGM:KIDS Community·US$465.9m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

KIDS Share Price Performance

US$18.23
-4.66 (-20.36%)
US$24.00
Fair Value
US$18.23
-4.66 (-20.36%)
24.0% undervalued intrinsic discount
US$24.00
Fair Value
Price US$18.23
AnalystConsensusTarget US$24.00
AnalystHighTarget US$33.19
AnalystLowTarget US$17.00

KIDS Community Narratives

·
Fair Value US$24 24.0% undervalued intrinsic discount

Expanding Global Reach Will Support Long-Term Outlook Amid Revenue Headwinds

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
·
Fair Value US$33.19 45.1% undervalued intrinsic discount

Global Population Growth And Healthcare Access Will Boost Pediatric Procedures

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$17 7.2% overvalued intrinsic discount

Rising Global Costs Will Constrain Revenue While Clinics Persist

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$33.19
45.1% undervalued intrinsic discount
Profit Margin
2.21%
Future PE
145.26x
Price in 2029
US$40.9

Trending Discussion

Updated Narratives

KIDS logo

KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions

Fair Value: US$17 7.2% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KIDS logo

KIDS: Solid Cash Generation And 2026 Launches Will Support Higher Upside

Fair Value: US$33.19 45.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KIDS logo

KIDS: Execution On 2026 Revenue Guidance Will Support Upside Potential

Fair Value: US$24 24.0% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

2 Risks
0 Rewards

OrthoPediatrics Corp. Key Details

US$243.3m

Revenue

US$65.5m

Cost of Revenue

US$177.8m

Gross Profit

US$217.5m

Other Expenses

-US$39.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-1.54
73.07%
-16.31%
30.3%
View Full Analysis

About KIDS

Founded
2006
Employees
602
CEO
David Bailey
WebsiteView website
www.orthopediatrics.com

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Recent KIDS News & Updates

Narrative Update May 07

KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions

The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.

Recent updates

No updates